MA33138B1 - Derives de benzothiazines, leur preparation et leur application a titre de medicaments - Google Patents

Derives de benzothiazines, leur preparation et leur application a titre de medicaments

Info

Publication number
MA33138B1
MA33138B1 MA34191A MA34191A MA33138B1 MA 33138 B1 MA33138 B1 MA 33138B1 MA 34191 A MA34191 A MA 34191A MA 34191 A MA34191 A MA 34191A MA 33138 B1 MA33138 B1 MA 33138B1
Authority
MA
Morocco
Prior art keywords
representing
group
benzotiaziazine
drugs
derivatives prepared
Prior art date
Application number
MA34191A
Other languages
Arabic (ar)
English (en)
Inventor
Michel Perez
Marie Lamothe
Didier Junquero
Yves Rival
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA33138B1 publication Critical patent/MA33138B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/021,2-Thiazines; Hydrogenated 1,2-thiazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

CETTE INVENTION CONCERNE DES DÉRIVÉS DES BENZOTHIAZINES CAPABLES D'INHIBER L'ENZYME 11ß-HSD1 NON SEULEMENT AU NIVEAU ENZYMATIQUE MAIS AUSSI AU NIVEAU CELLULAIRE. LES COMPOSÉS DE L'INVENTION SONT DE FORMULE GÉNÉRALE (I), R1 REPRÉSENTANT HYDROGÈNE OU OR1 REPRÉSENTANT UN ESTER OU UN ÉTHER, R2 REPRÉSENTANT UN GROUPE NAPHTYLE OU UN GROUPE 1,2,3,4-TÉTRAHYDRONAPHTALÈNE OU UN DIPHÉNYLE OU UN GROUPE PHÉNYLPYRIDINE OU UN GROUPE PHÉNYLE SUBSTITUÉ, R3 REPRÉSENTANT UN GROUPE MÉTHYLE OU ÉTHYLE, R4 ET R'4 REPRÉSENTANT HYDROGÈNE.
MA34191A 2009-03-03 2010-03-02 Derives de benzothiazines, leur preparation et leur application a titre de medicaments MA33138B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0951336A FR2942797B1 (fr) 2009-03-03 2009-03-03 Derives de benzothiazines, leur preparation et leur application a titre de medicaments
PCT/EP2010/052609 WO2010100139A1 (fr) 2009-03-03 2010-03-02 Dérivés des benzothiazines, leur préparation et leur application en tant que médicaments

Publications (1)

Publication Number Publication Date
MA33138B1 true MA33138B1 (fr) 2012-03-01

Family

ID=40790339

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34191A MA33138B1 (fr) 2009-03-03 2010-03-02 Derives de benzothiazines, leur preparation et leur application a titre de medicaments

Country Status (29)

Country Link
US (1) US9187438B2 (fr)
EP (1) EP2403840B1 (fr)
JP (1) JP5650139B2 (fr)
KR (1) KR101701531B1 (fr)
CN (1) CN102341379B (fr)
AR (1) AR075777A1 (fr)
AU (1) AU2010220335B2 (fr)
BR (1) BRPI1010243A2 (fr)
CA (1) CA2753630C (fr)
CL (1) CL2011002171A1 (fr)
CO (1) CO6501175A2 (fr)
ES (1) ES2483516T3 (fr)
FR (1) FR2942797B1 (fr)
GE (1) GEP20135832B (fr)
HK (1) HK1165802A1 (fr)
IL (1) IL214907A (fr)
MA (1) MA33138B1 (fr)
MX (1) MX2011008942A (fr)
MY (1) MY160819A (fr)
NZ (1) NZ595276A (fr)
PL (1) PL2403840T3 (fr)
RU (1) RU2523791C2 (fr)
SA (1) SA110310181B1 (fr)
SG (1) SG174208A1 (fr)
TN (1) TN2011000429A1 (fr)
TW (1) TWI495636B (fr)
UA (1) UA105040C2 (fr)
WO (1) WO2010100139A1 (fr)
ZA (1) ZA201107104B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
CN103271923B (zh) * 2013-06-28 2014-11-26 安徽中医学院 一种苯并噻嗪衍生物的医药用途
CN103304513B (zh) * 2013-06-28 2015-02-04 安徽中医学院 一类1,2-苯并噻嗪类化合物、制备方法及其应用
CN103275035B (zh) * 2013-06-28 2014-11-26 安徽中医学院 苯并噻嗪类化合物、其制备方法及其抗肿瘤用途
FR3035326B1 (fr) * 2015-04-21 2017-05-12 Pf Medicament Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique
CN106243046B (zh) * 2016-08-02 2019-07-05 南京工业大学 一种甲基二磺隆的制备方法
CA3057261A1 (fr) 2017-04-06 2018-10-11 Inventiva Nouveaux composes inhibiteurs de l'interaction yap/taz-tead et leur utilisation dans le traitement du mesotheliome malin
EP3632908A1 (fr) 2018-10-02 2020-04-08 Inventiva Inhibiteurs de l'interaction yap / taz-tead et leur utilisation dans le traitement du cancer
WO2023154412A1 (fr) * 2022-02-12 2023-08-17 Miralogx Llc Composés anti-inflammatoires, compositions pharmaceutiques et méthodes de traitement

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591584A (en) * 1968-08-27 1971-07-06 Pfizer Benzothiazine dioxides
US3808205A (en) * 1971-09-10 1974-04-30 Warner Lambert Co Process for the preparation of 4-hydroxy-3-carbamyl-2h-1,2-benzothiazine 1,1-dioxides and 4-hydroxy-3(2h)-1,2-benzothiazine carboxylate-1,1-dioxides
US4289879A (en) * 1980-09-29 1981-09-15 Pfizer Inc. Synthetic method and intermediate for piroxicam
FR2694295B1 (fr) * 1992-07-28 1994-09-02 Adir Nouveaux peptides dérivés de trifluoromethylcetones, leur procéde de préparation et les compositions pharmaceutiques qui les contiennent.
US5599811A (en) * 1995-02-21 1997-02-04 Warner-Lambert Company Benzothiazine dioxides as endothelin antagonists
AU2002212672A1 (en) * 2000-10-12 2002-04-22 Dr. Reddy's Research Foundation Salts of benzothiazine and benzoxazine derivatives and pharmaceutical compositions containing them
GB0224830D0 (en) * 2002-10-24 2002-12-04 Sterix Ltd Compound
DK1615647T3 (da) * 2003-04-11 2010-04-06 High Point Pharmaceuticals Llc Farmaceutisk anvendelse af kondenserede 1,2,4-triazoler
PL372356A1 (pl) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
US7981910B2 (en) * 2005-10-20 2011-07-19 Merck Sharp & Dohme Corp. Triazole derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase-1
CN101312951A (zh) * 2005-11-21 2008-11-26 盐野义制药株式会社 具有Ⅰ型11β羟基类固醇脱氢酶抑制活性的杂环化合物
JP2007197369A (ja) * 2006-01-26 2007-08-09 Sankyo Co Ltd ベンゾチアジン誘導体

Also Published As

Publication number Publication date
RU2011139014A (ru) 2013-04-10
TWI495636B (zh) 2015-08-11
SG174208A1 (en) 2011-10-28
FR2942797A1 (fr) 2010-09-10
CN102341379A (zh) 2012-02-01
RU2523791C2 (ru) 2014-07-27
NZ595276A (en) 2013-06-28
KR101701531B1 (ko) 2017-02-01
TN2011000429A1 (en) 2013-03-27
GEP20135832B (en) 2013-05-27
FR2942797B1 (fr) 2011-04-29
JP2012519203A (ja) 2012-08-23
ZA201107104B (en) 2012-05-30
EP2403840A1 (fr) 2012-01-11
UA105040C2 (uk) 2014-04-10
TW201035064A (en) 2010-10-01
AU2010220335B2 (en) 2014-05-29
CO6501175A2 (es) 2012-08-15
HK1165802A1 (en) 2012-10-12
AR075777A1 (es) 2011-04-27
AU2010220335A1 (en) 2011-10-13
WO2010100139A1 (fr) 2010-09-10
PL2403840T3 (pl) 2014-10-31
ES2483516T3 (es) 2014-08-06
IL214907A (en) 2015-02-26
KR20110122758A (ko) 2011-11-10
SA110310181B1 (ar) 2013-08-27
CL2011002171A1 (es) 2012-04-13
US20110319326A1 (en) 2011-12-29
US9187438B2 (en) 2015-11-17
MX2011008942A (es) 2011-09-27
JP5650139B2 (ja) 2015-01-07
BRPI1010243A2 (pt) 2016-03-22
CA2753630C (fr) 2017-05-30
CA2753630A1 (fr) 2010-09-10
MY160819A (en) 2017-03-31
CN102341379B (zh) 2015-08-26
IL214907A0 (en) 2011-11-30
EP2403840B1 (fr) 2014-05-14

Similar Documents

Publication Publication Date Title
MA33138B1 (fr) Derives de benzothiazines, leur preparation et leur application a titre de medicaments
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA55131B1 (fr) Nouveaux composés hétérocycliques
MA29649B1 (fr) Nouveaux derives de 2,4- dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
MA32391B1 (fr) Activateurs de la glucokinase
MA33761B1 (fr) Dispersion solide de rifaximine
PE20121312A1 (es) Metodo para preparar compuestos macrociclicos inhibidores de serina proteasas de hepatitis c
MA31703B1 (fr) Dérivés pyridiniques utilisés comme modulateurs du récepteur s1p1/edg1
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
MX2010002820A (es) Analogos de tiazolidindiona para tratamiento de hipertension.
WO2005074897A3 (fr) Auxiliaires de formulation
MA31741B1 (fr) Derives fongicides de 2-alkylthio-2-quinolinyloxy- acetamide
MA30082B1 (fr) Derives de pyrimidine
TW200716635A (en) Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
MA31285B1 (fr) Dihydro et tetrahydro oxazolopyrimidinones substituees, preparation et utilisation de celles-ci
CY1115643T1 (el) Διεγερτης νευρογενεσης ή θεραπευτικος παραγων νευροπαθειας που περιλαμβανει παραγωγα αλκυλ αιθερα ή αλας αυτου
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
MA31763B1 (fr) Inhibiteurs de kinase de type polo
MX2009011753A (es) Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
TNSN06370A1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
TW200607808A (en) Pyrido-pyrimidine derivatives, preparation thereof and application thereof
TN2010000173A1 (fr) Antagonistes de cgrp
MX2009004343A (es) Compuestos organicos.
MA28286A1 (fr) Dérivés de 1-N-phenyl-amino-1H-imidazole et compositions pharmaceutiques les contenant